
Orano Med has developed a patented chemical process allowing production of 212Pb on a large scale and at a reasonable cost
Development of TAT has long been hindered by a lack of supply of alpha emitting radioisotopes meeting three important criteria: purity meeting radiopharmaceutical standards, reliable production capacity sufficient to meet global needs, and economic competitiveness.
With a unique and proprietary source of raw material (Thorium 232), Orano Med has developed a patented chemical process allowing production of 212Pb on a large scale and at a reasonable cost.